Milan is also an important hub for the distribution of pharmaceuticals to the rest of Europe
The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
The company has reported total income of Rs. 211.62 crores during the period ended March 31, 2023
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
Wider reach for nutraceuticals portfolio in Europe, Turkey and Egypt
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
The company has reported total income of Rs. 4467.35 crores during the quarter ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
